GlassScriptPhysician profile
Kevin L Olson
NPI 1184600728
$2,416.68
in general payments reported to CMS, 2019-2025
27 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,460 · 2020: $295 · 2023: $89.92 · 2024: $269 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $661.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $520.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $357.73 | 2019-2025 | Breztri, Airsupra |
| Pfizer INC. | $194.61 | 2019-2025 | |
| Lilly USA, LLC | $186.06 | 2019-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $185.38 | 2019-2020 | |
| Amgen INC. | $147.76 | 2019 | |
| Sanofi-Aventis U.S. LLC | $91.83 | 2019 | |
| Janssen Pharmaceuticals, INC | $79.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.38 | 2019-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.31 | 2019 | |
| Abbvie INC. | $54.62 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $53.65 | 2019-2020 | |
| Genentech USA, INC. | $47.76 | 2019-2020 | |
| Exact Sciences Corporation | $45.44 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $43.84 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $36.61 | 2019-2020 | |
| Amarin Pharma, INC. | $36.17 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.07 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $33.19 | 2019 | |
| Bausch Health US, LLC | $21.05 | 2025 | Aplenzin |
| Bayer Healthcare Pharmaceuticals INC. | $17.07 | 2023 | |
| Shire North American Group INC | $16.82 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.65 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.69 | 2019 | |
| Medtronic, INC. | $14.44 | 2024 | Intellis Adaptivestim |
| Mylan Specialty L.P. | $12.03 | 2019 | |
| Sanofi Pasteur INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.